<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11542">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01836406</url>
  </required_header>
  <id_info>
    <org_study_id>4-2012-0485</org_study_id>
    <nct_id>NCT01836406</nct_id>
  </id_info>
  <brief_title>Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Partial nephrectomy is a widely accepted alternative to radical nephrectomy in patients with
      clinically localized, unilateral renal cell carcinoma and a normal contralateral kidney.
      Interruption of renal blood flow via pedicle clamping is often necessary during partial
      nephrectomy, especially for complex tumors with deep parenchymal invasion.
      Ischemia-reperfusion injury is a complex process involving several mechanisms including
      renal vasoconstriction, extensive tubular damage and glomerular injury. The investigators
      will examine the postoperative renal function of patients who received intraoperative
      ketorolac and remote ischemic preconditioning during partial nephrectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>serum creatinine</measure>
    <time_frame>at baseline, 2 hr, 12hr, 24 hr, 48 hr, 72 hr after clamping release</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance</measure>
    <time_frame>at baseline, 2 hr, 12hr, 24 hr, 48 hr, 72 hr after clamping release</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary NAG</measure>
    <time_frame>at base line, 2 hr, 12 hr after clamping release</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum NGAL</measure>
    <time_frame>at base line, 2 hr, 12 hr after clamping release</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Keromin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac tromethamine and remote ischemic preconditioning</intervention_name>
    <description>Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction</description>
    <arm_group_label>Keromin Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA l and ll

          -  age 20-65

          -  patients undergoing partial nephrectomy

        Exclusion Criteria:

          -  preoperative liver or renal dysfunction,

          -  coagulopathy,

          -  chronic alcoholism,

          -  hypersensitivity of NSAID,

          -  history of warfarin,

          -  history of gastric ulcer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>April 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ketorolac</keyword>
  <keyword>remote ischemic preconditioning</keyword>
  <keyword>partial nephrectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
